Sermorelin

aka GRF(1-29), GHRH(1-29), Geref, Geref Diagnostic, sermorelin acetate, SERM

Gh SecretagogueGh StimulationMuscle GrowthFat LossSleepIgf-1Body CompositionAnti-aging

Last reviewed April 27, 2026 by Doserr editorial team · 10 references on this page

Information on this page is sourced from published research and is for educational purposes only. It does not constitute medical advice.

TL;DR

What it is: A synthetic 29-amino-acid GHRH fragment that stimulates the pituitary to release endogenous GH, formerly FDA-approved as Geref, now compounded only.
What it's used for: Studied in children with GH deficiency (FDA-approved) and in older adults for GH and IGF-1 stimulation, off-label use for sleep and body composition is not supported by controlled evidence in healthy adults.
Evidence level:moderateModerate -- multiple controlled human trials exist, but approved data are pediatric, adult body composition and sleep data are limited.

Dose at a glance

	Beginner	Common	Higher end
Per dose	100-200 mcg	200-300 mcg	500 mcg
Daily total	100-200 mcg	200-300 mcg	500 mcg
Schedule	Once daily (pre-bed)	Once daily (pre-bed)	Once daily (pre-bed)
Cycle length	8 weeks	8-12 weeks on, 4 weeks off	3-6 months (clinical prescription pattern)

Synthesized from community-reported ranges. Not a recommendation. Route varies by compound — see Common route in What people report below.

Half-life: Approximately 10-20 minutes after subcutaneous injection in humans, rapidly cleaved by DPP-IV to the inactive GRF(3-29) metabolite. Well-characterized in published clinical pharmacology data. Shorter functional window than CJC-1295 (no DAC), which has four amino-acid substitutions that block DPP-4 cleavage.
Typical dose range: Doses below are from published research, not recommendations. FDA-approved pediatric dose: 30 mcg/kg SC once nightly at bedtime (PMID: 8772599). FDA-approved diagnostic dose: 1 mcg/kg IV bolus. Adult elderly studies: 0.5-1 mg SC twice daily (Corpas et al. 1992), 10 mcg/kg SC nightly (PMID: 9141536), 2 mg SC nightly (Vittone et al. 1997, cited via PMID: 32257855). GHRH-arginine stimulation test: 1 mcg/kg IV sermorelin + 0.5 g/kg IV arginine.
Route: Subcutaneous (SC) in all therapeutic studies and community use. Intravenous (IV) in diagnostic GHD stimulation testing only. No IV use in community context.
Evidence tier: moderate
Some human trials published; results limited or mixed.

Each topic links to the studies behind it. Click a topic to expand.

Dose-response for healthy adult (non-GHD) use is uncharacterized in published trials, all adult data come from elderly populations with age-related GH decline
Long-term safety beyond 12-36 months (pediatric trials) or 6-16 weeks (adult studies) has not been reported in the literature
Adult off-label use for body composition, sleep, or anti-aging is not supported by controlled evidence, all such use is compounded and off-label
Body composition outcomes in non-GHD adults are not established, the one controlled body composition trial (PMID: 9141536) was in elderly adults and found lean mass gain only in men with no fat mass change
Sustained vs. pulsatile dosing comparisons not formally studied, frequency of dosing significantly affects IGF-1 response (Corpas twice-daily vs. Vittone once-nightly results diverge)
Compounding quality, potency, and bioequivalence to former Geref are not verified by published research

Reconstitution math, both directions.

Log every dose, see your history, and save this protocol with one click.